Milvexian matching placebo
Sponsors
Janssen - Cilag International
Conditions
Acute Coronary SyndromeAcute Ischemic Stroke and High-Risk Transient Ischemic AttackAtrial Fibrillation
Phase 3
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack
RecruitingCTIS2022-501176-26-00
Start: 2023-08-04Target: 6471Updated: 2025-12-29
A Phase 3, Randomized, Double-Blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome
RecruitingCTIS2022-501418-69-00
Start: 2023-11-21Target: 8535Updated: 2025-12-08
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation
Active, not recruitingCTIS2022-501419-15-00
Start: 2023-08-23Target: 8867Updated: 2025-10-29